New hair loss pill shows promise in early trial

NCT ID NCT06527365

Ongoing Disease control Sponsor: Veradermics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 study tests an investigational oral drug called VDPHL01 in 70 adults with mild to moderate pattern baldness. Participants take a tablet once or twice daily for 12 months. Researchers will measure changes in hair count and ask participants about perceived benefit. The goal is to see if the drug is safe and effective for treating genetic hair loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VDPHL01 (an oral tablet)
What this could lead to: If successful, this could lead to a new daily pill to treat male and female pattern baldness.
What could go wrong: This is an early Phase 2 open-label study with only 70 people, so results may not apply broadly. The drug is still investigational and may not prove effective or safe in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia androgenetic alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGA ANDROGENETIC ALOPECIA MALE PATTERN BALDNESS

Contacts and locations

Locations

01

San Diego, California, 92123, United States
02

South Jordan, Utah, 84095, United States
03

Hackensack, New Jersey, 07601, United States
04

New Albany, Indiana, 47150, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.